title: Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests.
abstract: Several studies have evaluated thiazolidinedione therapy as medical treatments for some central nervous system disorders, such as cognitive deficits associated with neurodegenerative disorders. However, there is limited data to support a direct role for peroxisome proliferator-activated receptor-γ agonists in depression. Therefore, the aim of this study was to investigate antidepressant-like activity of rosiglitazone using the mouse tail suspension test and the rat forced swimming test, two models sensitive to the effects of antidepressants. In the tail suspension test, 5 days of treatment with rosiglitazone (8.5 or 17 mg/kg, orally) reduced immobility time. In the forced swimming test, rosiglitazone (6 or 12 mg/kg, orally) treatment decreased immobility time and increased climbing. These effects were not accompanied by any alteration in locomotor activity in the open field test. Rosiglitazone treatment (6 or 12 mg/kg, orally) significantly reduced plasma corticosterone levels in rats. GW9662 significantly inhibited the rosiglitazone-induced reduction in the duration of immobility. In summary, this study suggests that rosiglitazone possesses a specific antidepressant-like activity in behavioral models and that this effect may be mediated by reduction of plasma corticosterone level.
authors.affiliation: Department of Pharmacology, Faculty of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
authors.forename: Amany Ali
authors.initials: AA
authors.lastname: Eissa Ahmed
authors.forename: Nawal Mohammed
authors.initials: NM
authors.lastname: Al-Rasheed
authors.forename: Nouf Mohammed
authors.initials: NM
authors.lastname: Al-Rasheed
mesh_terms: D000813:Anilides / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003345:Corticosterone / Q000097:blood; D003866:Depressive Disorder / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D046353:Immobility Response, Tonic / Q000187:drug effects*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D047495:PPAR gamma / Q000819:agonists* / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D013550:Swimming; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D000928:Antidepressive Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D003345:Corticosterone